Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence.
Adenocarcinoma
/ pathology
Antineoplastic Agents
/ therapeutic use
Carcinoma, Adenosquamous
/ pathology
Carcinoma, Squamous Cell
/ pathology
Chemoradiotherapy
Combined Modality Therapy
Female
Humans
Hysterectomy
/ methods
Neoadjuvant Therapy
Neoplasm Staging
Practice Guidelines as Topic
Prognosis
Randomized Controlled Trials as Topic
Uterine Cervical Neoplasms
/ pathology
Cervical cancer
Concurrent chemoradiotherapy
Neoadjuvant chemotherapy
Radical hysterectomy
Stage II
Survival
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
12 02 2020
12 02 2020
Historique:
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
24
6
2021
Statut:
epublish
Résumé
To review and discuss the present evidence of surgery- and radiation-based treatment strategies for stage IIB cervical cancer. Recently, two randomized controlled trials compared the efficacy of neoadjuvant chemotherapy followed by radical hysterectomy (NACT + RH) with that of concurrent chemoradiotherapy (CCRT) for stage IB3-IIB cervical cancer. When these studies were combined (N = 1259), NACT + RH was associated with a shorter disease-free survival [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.13-1.64], but with a similar overall survival (HR 1.11, 95% CI 0.90-1.36) when compared with the findings for CCRT. Stage-specific analysis for stage IIB cervical cancer demonstrated that disease-free survival was significantly worse with NACT + RH than with CCRT (HR 1.90, 95% CI 1.25-2.89); however, no significant difference was observed for stage IB3-IIA cervical cancer. Based on the results of recent level I evidence, the standard treatment for stage IIB cervical cancer remains CCRT.
Identifiants
pubmed: 32052204
doi: 10.1007/s11912-020-0888-x
pii: 10.1007/s11912-020-0888-x
pmc: PMC7759090
mid: NIHMS1653186
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
28Subventions
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Références
Anticancer Res. 2018 Jun;38(6):3627-3634
pubmed: 29848719
Int J Gynecol Cancer. 2017 Feb;27(2):344-349
pubmed: 27984377
Cochrane Database Syst Rev. 2012 Dec 12;12:CD007406
pubmed: 23235641
J Clin Oncol. 2004 Aug 1;22(15):3113-9
pubmed: 15284262
Oncol Res Treat. 2016;39(9):522-4
pubmed: 27614740
J Gynecol Oncol. 2012 Oct;23(4):235-41
pubmed: 23094126
Onco Targets Ther. 2019 Mar 07;12:1881-1891
pubmed: 30881040
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Int J Gynecol Cancer. 2016 May;26(4):729-36
pubmed: 26905327
J Clin Oncol. 1999 May;17(5):1339-48
pubmed: 10334517
Gynecol Oncol. 2002 Jan;84(1):115-9
pubmed: 11748986
Cochrane Database Syst Rev. 2016 Nov 22;11:CD005342
pubmed: 27873308
J Clin Oncol. 2018 Jun 1;36(16):1548-1555
pubmed: 29432076
N Engl J Med. 1999 Apr 15;340(15):1144-53
pubmed: 10202165
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Radiology. 2015 Mar;274(3):734-41
pubmed: 25299787
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD006248
pubmed: 23440805
Lancet. 2001 Sep 8;358(9284):781-6
pubmed: 11564482
Eur J Cancer. 2003 Nov;39(17):2470-86
pubmed: 14602133
J Clin Oncol. 2018 Jun 1;36(16):1543-1547
pubmed: 29668367
Am J Clin Oncol. 2010 Dec;33(6):583-6
pubmed: 20065848
J Obstet Gynaecol Res. 2006 Jun;32(3):315-23
pubmed: 16764623
Curr Oncol Rep. 1999 Sep;1(1):41-6
pubmed: 11122796
Gynecol Oncol. 2007 Jan;104(1):186-91
pubmed: 16996115
Gynecol Oncol. 2016 May;141(2):231-239
pubmed: 26115978
Eur J Gynaecol Oncol. 2015;36(1):54-8
pubmed: 25872335
J Clin Med. 2019 Jan 30;8(2):
pubmed: 30704058
Gynecol Oncol. 2012 May;125(2):292-6
pubmed: 22293041
Onco Targets Ther. 2014 Nov 26;7:2155-60
pubmed: 25473297
J Clin Oncol. 2011 May 1;29(13):1678-85
pubmed: 21444871
Chin J Cancer Res. 2019 Apr;31(2):295-305
pubmed: 31156300
Gynecol Oncol. 2008 Sep;110(3):308-15
pubmed: 18606439
BMC Cancer. 2014 Feb 04;14:63
pubmed: 24495453
J Obstet Gynaecol Res. 2016 Sep;42(9):1069-79
pubmed: 27338217
Expert Rev Anticancer Ther. 2010 Mar;10(3):451-60
pubmed: 20214525
Int J Gynecol Cancer. 2005 Nov-Dec;15(6):995-1001
pubmed: 16343175
Gynecol Oncol. 2007 Aug;106(2):362-9
pubmed: 17493669
Int J Clin Oncol. 2019 Jan;24(1):1-19
pubmed: 30291468
Int J Gynecol Cancer. 2008 Jul-Aug;18(4):766-72
pubmed: 17892456
Br J Cancer. 2003 Sep 1;89(5):834-9
pubmed: 12942114
J Clin Oncol. 2018 Sep 20;36(27):2811-2812
pubmed: 29897830
J Clin Oncol. 2015 Jul 1;33(19):2129-35
pubmed: 25732161
Int J Clin Oncol. 2016 Dec;21(6):1128-1135
pubmed: 27380169
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S944-51
pubmed: 26268452
Cancer. 2011 Mar 1;117(5):948-56
pubmed: 20945318
Br J Cancer. 2013 May 28;108(10):1957-63
pubmed: 23640393
J Gynecol Oncol. 2019 Jul;30(4):e82
pubmed: 31074236
J Clin Oncol. 2000 Apr;18(8):1606-13
pubmed: 10764420
Insights Imaging. 2017 Oct;8(5):471-481
pubmed: 28828723
N Engl J Med. 1999 Apr 15;340(15):1154-61
pubmed: 10202166
Curr Opin Oncol. 2018 Sep;30(5):323-329
pubmed: 29994902
Int J Gynecol Cancer. 2016 Sep;26(7):1252-7
pubmed: 27284726
J Clin Oncol. 2002 Jan 1;20(1):179-88
pubmed: 11773168
Lancet. 2019 Jan 12;393(10167):169-182
pubmed: 30638582
Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S36-40
pubmed: 18586309
Gynecol Oncol. 2018 Aug;150(2):288-292
pubmed: 29807695
Lancet. 1997 Aug 23;350(9077):535-40
pubmed: 9284774
J Gynecol Oncol. 2017 Mar;28(2):e19
pubmed: 28028992
Eur J Surg Oncol. 2013 Feb;39(2):115-24
pubmed: 23084091
Gynecol Oncol. 2016 Feb;140(2):253-8
pubmed: 26701414
Am J Cancer Res. 2019 Jun 01;9(6):1224-1234
pubmed: 31285954
Medicine (Baltimore). 2018 Jun;97(22):e10913
pubmed: 29851821
Int J Gynecol Cancer. 2014 Sep;24(7):1333-40
pubmed: 25078340
Radiology. 2013 Mar;266(3):717-40
pubmed: 23431227
Int J Gynecol Cancer. 2016 Sep;26(7):1258-63
pubmed: 27258731
Gynecol Oncol. 2014 Aug;134(2):419-25
pubmed: 24918866
Int J Gynecol Cancer. 2018 Oct;28(8):1576-1583
pubmed: 30095702
Onco Targets Ther. 2018 Sep 19;11:5527-5533
pubmed: 30275701
Mol Clin Oncol. 2014 Mar;2(2):240-244
pubmed: 24649340
Ann Oncol. 2017 Jul 1;28(suppl_4):iv72-iv83
pubmed: 28881916
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD008285
pubmed: 20091664
Gynecol Oncol. 1997 Oct;67(1):61-9
pubmed: 9345358
Virchows Arch. 2018 Jun;472(6):919-936
pubmed: 29725757
Br J Cancer. 2013 Oct 29;109(9):2506
pubmed: 24064978
Int J Gynaecol Obstet. 2018 Mar;140(3):299-306
pubmed: 29194646
Eur J Cancer. 2012 Oct;48(15):2353-60
pubmed: 22503395
J Gynecol Oncol. 2017 May;28(3):e22
pubmed: 28382794
Gynecol Oncol. 2019 Jan;152(1):87-93
pubmed: 30389105
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S96-101
pubmed: 25341589
Eur J Gynaecol Oncol. 2003;24(1):51-9
pubmed: 12691318
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Gynaecol Obstet. 2019 Apr;145(1):129-135
pubmed: 30656645
Gynecol Oncol. 2014 Nov;135(2):208-12
pubmed: 25152438
J Gynecol Oncol. 2015 Apr;26(2):118-24
pubmed: 25686397
Psychooncology. 2009 May;18(5):476-82
pubmed: 18702067
Eur J Surg Oncol. 2019 Aug;45(8):1417-1424
pubmed: 30846298
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv262
pubmed: 29741577
Int J Gynecol Cancer. 2017 Mar;27(3):514-522
pubmed: 28129238
Gynecol Oncol. 2011 Nov;123(2):241-7
pubmed: 21820708